Comparative Pharmacology
Head-to-head clinical analysis: SULFADIAZINE SODIUM versus TRIMETHOPRIM SULFAMETHOXAZOLE.
Head-to-head clinical analysis: SULFADIAZINE SODIUM versus TRIMETHOPRIM SULFAMETHOXAZOLE.
SULFADIAZINE SODIUM vs Trimethoprim-Sulfamethoxazole
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfadiazine is a competitive inhibitor of dihydropteroate synthase, blocking the conversion of p-aminobenzoic acid (PABA) to dihydropteroate, thereby inhibiting bacterial folic acid synthesis.
Sulfamethoxazole inhibits dihydropteroate synthase, blocking para-aminobenzoic acid incorporation into dihydrofolate; trimethoprim inhibits dihydrofolate reductase, preventing tetrahydrofolate formation. Sequential blockade of folate synthesis.
2-4 g IV initially, then 1-2 g IV every 6-8 hours; oral dose: 2-4 g loading, then 1-2 g every 6 hours
Oral: 160 mg TMP/800 mg SMX every 12 hours; IV: 8-10 mg/kg/day (based on TMP) in 2-4 divided doses
None Documented
None Documented
Terminal elimination half-life: 10-20 hours (prolonged in renal impairment; context: requires dose adjustment in CrCl <50 mL/min).
Trimethoprim: 8-10 hours (normal renal function); prolonged to 24-30 hours in severe renal impairment (CrCl <10 mL/min). Sulfamethoxazole: 9-11 hours; prolonged in renal failure. The combination retains a half-life of ~10-12 hours in healthy adults, requiring dose adjustment in renal impairment.
Renal: 60-85% (via glomerular filtration and tubular secretion, with acetylation in liver reducing solubility and increasing crystalluria risk). Biliary/fecal: less than 15%. Unchanged drug and acetylated metabolites both excreted.
Trimethoprim: 50-60% excreted unchanged in urine via glomerular filtration and tubular secretion; 10-20% as metabolites. Sulfamethoxazole: 20-30% excreted unchanged in urine; 50-70% as N4-acetylated metabolite. Both undergo minimal biliary/fecal elimination (<5% total).
Category D/X
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic